A New Perspective on Cancer Immunotherapy
This article was originally published in Start Up
Many believe that for therapeutic cancer vaccines, a more flexible two-stage system of proof-of-principle trials followed by efficacy trials should replace the current Phase I-III structure. That's because the paradigm used for oncology drug development is based on criteria developed for cytotoxic agents, which present a very different toxicity profile, metabolism, and manner of biological and clinical response.
You may also be interested in...
GSK's first immunotherapy is still 4-5 years away, but it is already commissioning a companion diagnostic for it. By striking a deal with Abbott for a commercial screening test this early, the pharma may be laying the groundwork to address any regulatory concerns around using the test to enrich its clinical trials populations, which could allow for lower numbers of patients to be enrolled in order to prove efficacy.
Immunotherapy has seen its share of failures in recent months, but T-cell oriented therapies are by no means dead in the water and therapeutic cancer vaccines continue to attract funding. This month START-UP profiles three companies that nevertheless have been able to attract funding . They aim to avoid the difficulties that have sunk other efforts to commercialize immunotherapies. The firms are transplanting T cells along with same-donor bone marrow to fight infection, delivering powerful cytokines and other therapeutic payloads via T-cell receptor targeting, and genetically enhancing the ability of T-cell receptors to recognize antigens before growing those T cells in culture and re-infusing them into a patient's body.
The first big reveal has arrived for GlobeImmune. On November 1, the company presented positive interim Phase II clinical trials data at the 2008 American Association for the Study of Liver Diseases meeting showing that its GI-5005 hepatitis C vaccine doubled viral clearance in all major patient populations tested in its randomized, multi-center trial. These data represent early but important evidence that a patient's natural immune response can be harnessed to positively influence important virologic endpoints with the potential to impact the course of chronic HCV infection.